Abstract-Long-term administration of erythropoietin (EPO) frequently causes hypertension in humans and animals with chronic renal failure (CRF). We recently demonstrated that EPO-induced hypertension is hematocrit independent and accompanied by elevated cytosolic [Ca 2ϩ ] i and nitric oxide (NO) resistance. This study was undertaken to examine the effects of therapy with EPO alone or together with calcium channel blockade on NO metabolism. Urinary excretion of NO metabolites (NOx) and thoracic aorta and kidney endothelial and inducible NO synthases (eNOS and iNOS) were studied in 4 groups of 6 nephrectomized rats treated with either placebo, EPO, the calcium channel blocker felodipine, or EPO plus felodipine for 6 weeks. A group of sham-operated placebo-treated animals served as control. 1-3 Several factors have been implicated in the pathogenesis of EPO-induced hypertension. Chief among them is the resulting rise in hematocrit, which is thought to raise vascular resistance by increase in blood viscosity, loss of hypoxic vasodilation, and enhanced competition by hemoglobin for endothelium-derived nitric oxide (NO). [4][5][6][7] Other proposed mechanisms include volume expansion, increased endothelin production, 8 enhanced tissue renin-angiotensin activity, 9 and direct vasopressor action of EPO.
10In a series of recent studies, we demonstrated that EPOinduced hypertension is not due to the associated increase in hematocrit or erythrocyte mass.11 This was based on the observation that hypertension occurred in both iron-deficient and iron-sufficient uremic rats receiving long-term EPO therapy despite divergent hematocrits. Moreover, repeated red blood cell transfusions did not raise arterial blood pressure despite complete correction of anemia in the uremic animals.11 Accordingly, these experiments provided convincing evidence that EPO-induced hypertension is not related to the erythropoietic action of the hormone. We further found that long-term EPO administration leads to a significant rise in resting cytosolic [Ca 2ϩ ] i above the elevated values seen in untreated rats with chronic renal failure (CRF).11 Moreover, EPO therapy normalized the defective stimulated surge in [Ca 2ϩ ] i seen in the untreated CRF animals. The study further showed that long-term EPO administration resulted in a marked reduction in hypotensive response in vivo and vasorelaxation response in vitro to administration of the NO donor sodium nitroprusside. These observations pointed to NO resistance as a possible cause of EPO-induced hypertension. Since the vasodilatory action of NO is mediated by cGMP-induced fall in [Ca 2ϩ ] i , we hypothesized that the observed NO resistance may be due to the demonstrated rise in resting and/or stimulated [Ca 2ϩ ] i with EPO therapy. 11 The present study was designed to explore the effect of long-term EPO therapy with and without calcium channel blockade on NO production and NO synthase (NOS) expression.
Methods
Animal ModelsMale Sprague-Dawley rats (Harlan Sprague Dawley Inc) with an average we...